{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"52.2","value":"0"},{"groupId":"OG001","lowerLimit":"24.4","upperLimit":"71.1","value":"47"},{"groupId":"OG002","lowerLimit":"13.9","upperLimit":"68.4","value":"38"},{"groupId":"OG003","lowerLimit":"11.9","upperLimit":"54.3","value":"30"},{"groupId":"OG004","lowerLimit":"12.2","upperLimit":"73.8","value":"40"},{"groupId":"OG005","lowerLimit":"16.7","upperLimit":"76.6","value":"45"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"10"},{"groupId":"OG005","value":"11"}],"units":"Participants"}],"description":"Percentage of participants with CR plus CRh (CR, Molecular CR \\[CRm\\]), Cytogenetic CR \\[CRc\\], CRh) is re-ported. CR is defined as bone marrow blasts \\<5 % (in aspirate with spicules and 200 nucleated cells), no blasts with auer rods, no extramedullary disease, ANC \\>=1000/μL, platelet count \\>=100,000/μL and transfusion independ-ence. CRc is defined as CR with no residual cytogenetic abnormalities. CRm is de-fined as CR with undetectable IDH1m MRD and CRh is defined as bone marrow blasts and partial recovery of peripheral blood counts (platelet count \\>50 × 10\\^9/L and ANC \\> 0.5 × 10\\^9/L).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with R/R AML or MDS who were previously treated with FT-2102 and who underwent HSCT on-study then relapsed post-HSCT received single agent of FT-2102 150 mg BID in continuous 28-day cycles.","id":"OG000","title":"Phase 2: Cohort 3; FT-2102 (Single Agent)"},{"description":"Participants with R/R AML that is naïve to prior hypomethylating therapy and IDH1 inhibitor therapy received combination therapy of azacitidine 75 mg/m\\^2 + FT-2102 150 mg BID in continuous 28-day cycles.","id":"OG001","title":"Phase 2: Cohort 4; FT-2102 + Azacitidine (Combination Therapy)"},{"description":"Participants with R/R AML/MDS that have inadequately responded to or have progressed on prior hypo-methylating therapy received combination therapy of azacitidine 75 mg/m\\^2 + FT-2102 150 mg BID in continuous 28-day cycles.","id":"OG002","title":"Phase 2: Cohort 5; FT-2102 + Azacitidine (Combination Therapy)"},{"description":"Participants with R/R AML/MDS that have been previously treated with single agent FT-2102 as their last therapy prior to study enrolment received combination therapy of azacitidine + FT-2102 150 mg BID in continuous 28-day cycles. Participants from the FT-2102 single agent cohorts of this study allowed to be enrolled in Cohort 6 after their disease progression.","id":"OG003","title":"Phase 2: Cohort 6; FT-2102 + Azacitidine (Combination Therapy)"},{"description":"Participants who have not received any prior AML treatment but may have received a prior treatment for another hematologic malignancy be given single agent of FT-2102 150 mg BID in continuous 28-day cycles.","id":"OG004","title":"Phase 2: Cohort 7; FT-2102 (Single Agent)"},{"description":"Participants who have not received any prior AML treatment but may have received a prior treatment for another hematologic malignancy be given combination therapy of azacitidine 75 mg/m\\^2 + FT-2102 150 mg BID in continuous 28-day cycles.","id":"OG005","title":"Phase 2: Cohort 8; FT-2102 + Azacitidine (Combination Therapy)"}],"paramType":"NUMBER","populationDescription":"FAS included all the participants who were enrolled in the study and have received at least one dose of FT-2102. This outcome measure is applicable for Cohort 3, 4, 5, 6, 7 and 8. Here, Overall Number of Participants Analyzed = participants with available data for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Phase 2: up to 3 weeks post last dose of study drug or until the introduction of new anticancer therapy, whichever is earlier (up to 82 months)","title":"Phase 2, Cohort 3, 4, 5, 6, 7, 8: Percentage of Participants With CR Plus CRh for Acute Myeloid Leukemia Assessed by Investigator Based on IWG Response Criteria","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}